Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Pfizer

Roivant Sciences Ltd

Shares of Roivant Sciences Ltd. ROIV, -1.13% and Pfizer Inc. PFE, -1.73% gained ground premarket on Monday after Roche Holding AG RHHBY, +0.51% agreed to buy immunology company Telavant for $7.1 billion.

Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion

The Swiss pharma giant said it will begin late-stage trials on the experimental antibody therapy “as soon as possible” to help bring it to patients suffering from inflammatory bowel disease.

Roche Secures Promising Bowel Disease Therapy—Which Could Help Treat Crohn's—In $7.1 Billion Telavant Deal

The deal is the latest example of a big pharma company turning to the deal table to bolster its pipeline of autoimmune drugs.

Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion

It will buy immunology company Telavant Holdings from Roivant Sciences and Pfizer.

Roche Agrees $7.1 Billion for Drug Company

Roche has agreed to pay US$7.1 billion for an early-stage inflammatory bowel disease treatment developed by US rivals Roivant and Pfizer. For its money, the Swiss group will get the rights to develop, manufacture and commercialise the experimental drug known as RVT-3101 in the US and Japan.

Roche splashes US$7.1 billion on new irritable bowel drug

Swiss health care company Roche announced it would acquire Telavant Holdings Monday, in a deal worth $7.1 billion.

Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant Holdings

Roche on Monday said it will buy Telavant, a developer of a new treatment for inflamatory bowel diseases, for an initial $7.1 billion from American biopharma company Roivant Holdings and Pfizer Inc.

Roche buys Telavant Holdings for $7.1 billion

Basel, 23 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc.. The agreement includes the development, manufacturing and commercialisation rights in the US and Japan for Televant's RVT-3101, a novel TL1A directed antibody. RVT-3101 is a promising new therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Inflammatory bowel disease is a group of chronic gastrointestinal disorders with almost 8 million people diagnosed worldwide and 80% of all individuals not experiencing lasting remission.1 Given the antibody's novel mode of action targeting both inflammation and fibrosis, it has potential to be applied in multiple other diseases.

[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant

Pfizer's revenue has taken a big hit because of lower COVID-19-related sales. Roche just released third-quarter earnings.

Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Results from the CUPISCO study to be presented as a late breaking abstract at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting.

New Research from Foundation Medicine and Roche Demonstrates Improved Outcomes Following Treatment Based on Comprehensive Genomic Profiling in Patients with Cancer of Unknown Primary Origin (CUP)

Roche (RHHBY) reports a sales decline in the first nine months of 2023 as COVID-19-test sales continue to dent its top line. Currency rate fluctuations also impact its results.

Roche (RHHBY) Nine Months' Sales Fall on Lower COVID-19 Test Sale

Roche stock skidded early Thursday after the Swiss drugmaker said declining demand for Covid products weighed on third-quarter sales.

Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, Guidance

Royalty Pharma

Royalty Pharma said on Thursday it has purchased additional royalties on Roche and PTC Therapeutics' oral spinal muscular atrophy (SMA) drug for an upfront payment of $1 billion.

Royalty Pharma to pay $1 bln for Roche's SMA drug royalties

Roche said nine-month sales slipped 6% to 44.1 billion Swiss francs ($49.1 billion), hit by a sharp decline in sales of COVID-19 products and as a strong Swiss franc weighed on the value of overseas sales.

Roche's 9M sales down 6% on currency headwinds, drop in COVID sales

Basel, 19 October 2023 Group sales grow by 1%1 at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarter Excluding COVID-19 products, Group sales increase by 9% Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicines Diagnostics Division's base business increases by 7%; overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022 Highlights in the third quarter of 2023: EU approval of Evrysdi for babies under two months old with spinal muscular atrophy First approval of subcutaneous form of cancer immunotherapy Tecentriq Positive phase III data for Alecensa (early-stage lung cancer) and Ocrevus (subcutaneous injection; multiple sclerosis) Positive phase II data for zilebesiran (hypertension in patients at high risk of cardiovascular disease) and additional positive phase II data for fenebrutinib (multiple sclerosis) Positive longer-term efficacy and safety data for Ocrevus (multiple sclerosis) and Vabysmo (retinal vein occlusion, a severe eye disease) Launch of first validated test for earlier diagnosis of neonatal sepsis and new module to improve laboratory efficiency Outlook for 2023 confirmed Roche CEO Thomas Schinecker: “We achieved good results in the first nine months of 2023, more than compensating for the expected decline in demand for COVID-19 products. Our Group sales excluding COVID-19 products continued to grow strongly by +9% at constant exchange rates.

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products

AstraZeneca

Novo Nordisk

Regeneron Pharmaceuticals

NASHVILLE, Tenn. & TARRYTOWN, N.Y. & WILMINGTON, Del. & BAGSVAERD, Denmark & BASEL, Switzerland--(BUSINESS WIRE)--Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ (“Changing Healthcare for People of African Ancestry through an InterNational Genomics & Equity”) initiative to create better health care and outcomes for all. The Together for CHANGE initiative seeks to addr.

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

Basel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Elecsys IL-6 immunoassay has become the first IL-6 test to have a certified claim for use in diagnosis of neonatal sepsis, in countries accepting the CE Mark.*

Roche IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns

Basel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the primary analysis of the Phase III ALINA study demonstrating a statistically significant and clinically meaningful improvement in disease-free survival (DFS; primary endpoint). The study results showed that Alecensa® (alectinib) reduces the risk of disease recurrence or death by 76% (hazard ratio [HR]=0.24, 95% CI: 0.13-0.43, p

Roche's Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the primary analysis of the Phase III ALINA study demonstrating a statistically significant and clinically meaningful improvement in disease-free survival (DFS; primary endpoint). The study results showed that Alecensa® (alectinib) reduces the risk of disease recurrence or death by 76% (hazard ratio [HR]=0.24, 95% CI: 0.13-0.43, p

Genentech's Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer

Roche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis.

Roche's (RHHBY) MS Drug Reduces Brain Lesions in Phase II Study

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data from the Phase II FENopta study showing that investigational, oral fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis (RMS), with a consistent safety profile to other fenebrutinib trials. The late-breaking data were featured in an oral presentation at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Amer.

Late-Breaking Data for Genentech's BTK Inhibitor Fenebrutinib Show Brain Penetration and Significant Reduction in Lesions in Patients With Relapsing Multiple Sclerosis

Basel, 13 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data from the Phase II FENopta study showing that investigational, oral fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis (RMS) with a consistent safety profile to other fenebrutinib trials. The late-breaking data were featured in an oral presentation at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis). “These interesting results raise the possibility that fenebrutinib slows MS disease progression in part by acting directly within the brain,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “These data, which we are currently confirming in pivotal trials of both relapsing and progressive MS, suggest that fenebrutinib may have the potential to counteract acute and chronic inflammation within the brain to reduce disease activity in people with MS.” Brain penetrance was measured by the level of fenebrutinib in the cerebrospinal fluid (CSF) of a subgroup of 11 patients with RMS. After 12 weeks of continuous treatment, the mean fenebrutinib concentration was 43.1 ng/mL. Similar fenebrutinib concentrations can produce near-maximal inhibition (IC90) in preclinical studies. Thus, the level of fenebrutinib in the brain and central nervous system may conceivably become high enough to reduce MS disease activity and progression in patients. Fenebrutinib significantly reduced the total number of new T1 gadolinium-enhancing (T1 Gd+) brain lesions which are markers of active inflammation, and the total number of new or enlarging T2-weighted (T2) brain lesions, which represent the amount of disease burden or chronic lesion load. A rapid onset of lesion reduction was observed by 4 weeks, with relative reductions of 92% and 90% in T1 Gd+ lesions and relative reductions of 90% and 95% in T2 lesions observed at 8 and 12 weeks, respectively.

Late-breaking data for Roche's BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis

Basel, 12 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new clinical and real-world data for OCREVUS® (ocrelizumab), demonstrating its role in continuing to transform care for people living with relapsing or primary progressive multiple sclerosis (RMS or PPMS) presented at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis). OCREVUS is the first and only disease-modifying treatment (DMT) in MS to benefit both people with RMS and PPMS and now has 10 years of follow-up data from its three Phase III trials.

New data for Roche's OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new clinical and real-world data for Ocrevus® (ocrelizumab) demonstrating its role in continuing to transform care for people living with relapsing or primary progressive multiple sclerosis (RMS or PPMS) presented at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis). Ocrevus is the first and onl.

New Data for Genentech's Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided

Basel, 11 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced late-breaking data from the Phase III OCARINA II study. Study results demonstrate the effect of OCREVUS® (ocrelizumab) as an investigational twice-yearly, 10-minute subcutaneous injection on pharmacokinetic, biomarker, and MRI measures in patients with relapsing or primary progressive multiple sclerosis (RMS or PPMS). The data will be presented in a poster at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis).

Roche's OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions

News for Roche Holding AG Stock (RHHBY)